help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spicer, L. J.
Right arrow Articles by Hammond, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spicer, L. J.
Right arrow Articles by Hammond, J. M.

Endocrinology, Vol 120, 2375-2382, Copyright © 1987 by Endocrine Society

ARTICLES

2-Hydroxyestradiol modulates a facilitative action of catecholamines on porcine granulosa cells

LJ Spicer and JM Hammond

Recent studies have disclosed a novel intraovarian paracrine system whereby catecholestrogens [e.g. 2-hydroxyestradiol (2-OH-E2)], synthesized locally from estradiol (E2) can stimulate progesterone secretion by granulosa cells (GC). Since these studies suggested that effects of 2-OH-E2 were discrete from those of E2, the present studies were undertaken to determine if the effects of 2-OH-E2 could be mediated through or interact with the catecholamine response system of GC. First, the effects of 2-OH-E2 were compared with those of E2 and epinephrine (EPI) using undifferentiated porcine GC. After 4 days of treatment, saturating concentrations of EPI (1 microgram/ml), 2-OH-E2 (4 micrograms/ml), and E2 (1 microgram/ml) stimulated progesterone production per cell 2-, 9-, and 10-fold, respectively. Saturating doses of EPI plus 2-OH-E2 or EPI plus E2 caused further significant increases in progesterone production above the effects of any single treatment, and the effects of EPI plus 2-OH-E2 were significantly greater than that of EPI plus E2. Isoproterenol mimicked the effect of EPI. Neither propranolol (a beta-antagonist) nor phentolamine (an alpha-antagonist) blocked the effects of 2-OH-E2, suggesting that effects of 2-OH-E2 were not mediated through alpha- or beta-adrenergic receptors. Collectively, these data suggest that 2-OH-E2, beta-adrenergic agonists, and E2 use separate response systems. To further evaluate the interaction between catecholamines and 2-OH-E2, GC were treated with increasing doses of 2- OH-E2 with or without EPI or isoproterenol. EPI and isoproterenol caused a synergistic increase in progesterone production above that induced by all doses of 2-OH-E2 along (average 3.8 +/- 0.7- and 3.2 +/- 0.4-fold enhancement for EPI and isoproterenol, respectively). This synergistic effect was blocked with addition of propranolol, indicating a beta-adrenergic mediation for the catecholamine portion of this effect. Studies using the catechol-O-methyltransferase inhibitor, U- 0521, and the O-methyl derivative of EPI, metanephrine, suggested that catechol-O-methyltransferase present in GC dramatically reduces the potency of EPI, but is not involved in the synergism between EPI and 2- OH-E2. In conclusion, 2-OH-E2 is a more efficacious stimulator of progesterone secretion than catecholamines and synergizes with beta- adrenergic agonists to further stimulate progesterone production by GC. The mechanism by which catecholamines and 2-OH-E2 interact within GC is unknown.4+owever, this catecholamine/2-OH-E2 interaction




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society